Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - JPMorgan initiated coverage on Cyient DLM Ltd (CYIENTDL:IN) with an Underweight rating and a price target of INR450.00 on Wednesday.
The research firm cited growth challenges for the company in FY26, pointing to a soft order book that has remained flat for the last three quarters, with the fourth quarter of 2025 down 12% year-over-year.
JPMorgan also highlighted the absence of revenues from Bharat Electronics (NSE:BAJE), as the renewal contract has not yet materialized, and noted concerns about the company’s higher exports mix, which represented 59% of revenues in FY25.
The stock has underperformed year-to-date, falling 33% compared to peers’ 16% decline and Nifty’s 6% gain, which JPMorgan believes already reflects the negative outlook.
While acknowledging Cyient DLM could be a structural play on Aerospace and Defense sectors that are in an upcycle, JPMorgan valued the stock at 25x June 2026 earnings, lower than peers Syrma and Kaynes, citing lower growth expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.